Gene therapy study for babies with fused skull bones
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This study tests a new treatment called ASO (antisense oligonucleotide) therapy on tissue samples from babies with syndromic craniosynostosis—a condition where skull bones fuse too early due to specific genetic changes. Researchers hope this approach could eventually help prevent or reduce the severity of this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 0 and 5 years old
- Your child has been diagnosed with syndromic craniosynostosis caused by specific genetic mutations (in FGFR1, FGFR2, FGFR3, TWIST1, TCF12, EFNB1, ERF, MSX2, or ALX4)
- Your child has already had or will have skull surgery, and tissue samples from that surgery can be used for research
- You and your child's other parent (or legal guardians) agree in writing to participate
- Your child's genetic diagnosis must be confirmed and clearly identified—not 'possibly' or 'unknown'
- There must be enough good-quality tissue available from surgery for the researchers to work with
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medical device that helps guide surgery for children with certain skull conditions (trigonocephaly or anterior plagiocephaly). The device is designed to make the surgery safer and more precise for children aged 4 to 24 months.
This study tests whether burosumab and vitamin D affect bone cells before and around the time of craniosynostosis surgery in children. It may help researchers understand treatment options for rare calcium and phosphate bone disorders that can affect skull growth.
This study is building a database of medical information and images from children with certain conditions affecting the face and skull, such as craniosynostosis, achondroplasia, and osteogenesis imperfecta. The goal is to better understand these conditions and improve future care.
This research study examines the bone structure and healing of the skull in babies with craniosynostosis (when skull bones fuse too early). Researchers will analyze bone samples to better understand how the condition affects bone development and strength.
This trial tests a gene therapy that uses a child's own stem cells to treat autosomal recessive osteopetrosis (a genetic bone disease). It aims to improve bone health and reduce complications like fractures and vision loss.
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
Hear when a new Craniosynostoses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.